Repligen Corporation Common Stock (RGEN)
Stock · NASDAQ · Health Care
$175.42as of 10/16/2026
Price chart
Active signals
RGEN Signal Track Record
How signals performed across all stocks →What RGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -2.2% | 40% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 24 | -4.1% | 38% | July 22, 2026 |
| Bollinger Band Breakdown | 22 | +3.3% | 55% | July 24, 2026 |
| Bollinger Band Breakout | 20 | -5.9% | 35% | September 24, 2026 |
| Any 20-session window (baseline) | -0.5% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 2,000
- Website
- www.repligen.com/
Fundamentals
- 1-day range
- $178.75$191.2
- Market cap
- $9.00B
- P/E (trailing)
- 244.54
- P/E (forward)
- 71.52
- EPS (trailing)
- $0.73
- Dividend yield
- —
- Beta
- 1.13
- Avg. volume
- 1.11M
How Repligen Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
20 analyst ratings
Repligen Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 3 Healthcare Stocks That Concern UsYahoo · 10/2/2026
- Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?Yahoo · 9/29/2026
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyYahoo · 9/25/2026
- AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyYahoo · 9/23/2026
- 3 Unpopular Stocks Walking a Fine LineYahoo · 9/23/2026
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Yahoo · 9/22/2026
- JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania StudyYahoo · 9/22/2026
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationYahoo · 9/21/2026
Insider Activity
Insider Actions →- Garland Jason K · September 25, 2026 · Tax Withholding421 @ $189.68
- Loeillot Olivier · September 24, 2026 · Option Exercise4.5K @ $155.38
- Loeillot Olivier · September 24, 2026 · Option Exercise8.4K @ $154.96
- Loeillot Olivier · September 24, 2026 · Sale4.5K @ $190
- Loeillot Olivier · September 24, 2026 · Sale8.4K @ $190
- Loeillot Olivier · September 21, 2026 · Option Exercise5.4K @ $141.79
- Loeillot Olivier · September 21, 2026 · Sale5.4K @ $180
- Loeillot Olivier · September 4, 2026 · Sale3.0K @ $165.9
- Loeillot Olivier · September 3, 2026 · Tax Withholding2.8K @ $169.61
- Hughes Violetta · September 1, 2026 · Tax Withholding277 @ $170.02
- Loeillot Olivier · August 20, 2026 · Option Exercise5.4K @ $141.79
- Loeillot Olivier · August 20, 2026 · Sale5.4K @ $180
- Garland Jason K · July 16, 2026 · Sale530 @ $150
- Garland Jason K · June 25, 2026 · Sale733 @ $145
- Mhatre Rohin · May 14, 2026 · Grant2.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 63.09M
- Total value held
- $6.62B
- Institutional holders
- 433
- Unknown5.99M
- Unknown4.88M
- Unknown2.89M
- Unknown2.77M
- Unknown2.40M
- Unknown1.78M
- Unknown1.53M
- Unknown1.52M
- Unknown1.40M
- Unknown1.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.